BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papanagnou P, Stivarou T, Tsironi M. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs. Pharmaceuticals (Basel) 2016;9:E24. [PMID: 27164115 DOI: 10.3390/ph9020024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Taskoparan B, Seza EG, Demirkol S, Tuncer S, Stefek M, Gure AO, Banerjee S. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Cell Oncol (Dordr) 2017;40:563-78. [PMID: 28929377 DOI: 10.1007/s13402-017-0351-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
2 Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, Eisinger-mathason TSK, Brem H, Tyler B, Skuli N. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene 2017;36:3037-47. [DOI: 10.1038/onc.2016.457] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
3 Schulten HJ. Pleiotropic Effects of Metformin on Cancer. Int J Mol Sci 2018;19:E2850. [PMID: 30241339 DOI: 10.3390/ijms19102850] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
4 Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A. Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. Onco Targets Ther 2019;12:319-39. [PMID: 30643430 DOI: 10.2147/OTT.S182685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
5 Papanagnou P, Stivarou T, Papageorgiou I, Papadopoulos GE, Pappas A. Marketed drugs used for the management of hypercholesterolemia as anticancer armament. Onco Targets Ther 2017;10:4393-411. [PMID: 28932124 DOI: 10.2147/OTT.S140483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
6 Khasabova IA, Khasabov SG, Olson JK, Uhelski ML, Kim AH, Albino-Ramírez AM, Wagner CL, Seybold VS, Simone DA. Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress. Pain 2019;160:688-701. [PMID: 30507781 DOI: 10.1097/j.pain.0000000000001448] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
7 Ge S, Zhang Q, Chen Y, Tian Y, Yang R, Chen X, Li F, Zhang B. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol 2021;415:115450. [PMID: 33577917 DOI: 10.1016/j.taap.2021.115450] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Dong C, Kern NR, Anderson KR, Zhang XF, Miwa JM, Im W. Dynamics and Interactions of GPI-Linked lynx1 Protein with/without Nicotinic Acetylcholine Receptor in Membrane Bilayers. J Phys Chem B 2020;124:4017-25. [PMID: 32208709 DOI: 10.1021/acs.jpcb.0c00159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dankner R, Roth J. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Diabet Med. 2020;37:194-202. [PMID: 31769894 DOI: 10.1111/dme.14179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
10 Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne) 2020;11:191. [PMID: 32425881 DOI: 10.3389/fendo.2020.00191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
11 Podhorecka M. Metformin - its anti-cancer effects in hematologic malignancies. Oncol Rev 2021;15:514. [PMID: 33747367 DOI: 10.4081/oncol.2021.514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cunha Júnior AD, Pericole FV, Carvalheira JBC. Metformin and blood cancers. Clinics (Sao Paulo) 2018;73:e412s. [PMID: 30208162 DOI: 10.6061/clinics/2018/e412s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
13 Kersh AE, Ng S, Chang YM, Sasaki M, Thomas SN, Kissick HT, Lesinski GB, Kudchadkar RR, Waller EK, Pollack BP. Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. J Clin Pharmacol 2018;58:7-24. [PMID: 29136276 DOI: 10.1002/jcph.1028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Liu W, Li Y, Li L, Shangguan J, Liu Y, Ni T, Wang Y, Kang J. A Sensitive Colorimetric Determination of Metformin Based on Gold Nanoparticles Aggregation in Salt Solution. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202200001] [Reference Citation Analysis]